



Stelara[®] (ustekinumab) – New warning

- On June 8, 2018, the FDA approved an update to the *Warnings and Precautions* section of the [Stelara \(ustekinumab\)](#) drug label regarding noninfectious pneumonia.
- Stelara is indicated for the treatment of psoriasis, psoriatic arthritis and Crohn's Disease.
- Cases of interstitial pneumonia, eosinophilic pneumonia and cryptogenic organizing pneumonia have been reported during post-approval use of Stelara. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses.
 - Serious outcomes have included respiratory failure and prolonged hospitalization.
 - Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. If diagnosis is confirmed, discontinue Stelara and institute appropriate treatment.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.